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Abstract. Aberrant DNA methylation plays a pivotal role in carcinogenesis and its mapping is likely to provide biomarkers for
improved diagnostic and risk assessment in prostate cancer (PCa). We quantified and compared absolute methylation levels
among 28 candidate genes in 48 PCa and 29 benign prostate hyperplasia (BPH) samples using the pyrosequencing (PSQ) method
to identify genes with diagnostic and prognostic potential.
RARB, HIN1, BCL2, GSTP1, CCND2, EGFR5, APC, RASSF1A, MDR1, NKX2-5, CDH13, DPYS, PTGS2, EDNRB, MAL,
PDLIM4, HLAa, ESR1 and TIG1 were highly methylated in PCa compared to BPH (p < 0.001), while SERPINB5, CDH1,
TWIST1, DAPK1, THRB, MCAM, SLIT2, CDKN2a and SFN were not. RARB methylation above 21% completely distinguished
PCa from BPH. Separation based on methylation level of SFN, SLIT2 and SERPINB5 distinguished low and high Gleason score
cancers, e.g. SFN and SERPINB5 together correctly classified 81% and 77% of high and low Gleason score cancers respectively.
Several genes including CDH1 previously reported as methylation markers in PCa were not confirmed in our study. Increasing
age was positively associated with gene methylation (p < 0.0001).
Accurate quantitative measurement of gene methylation in PCa appears promising and further validation of genes like RARB,
HIN1, BCL2, APC and GSTP1 is warranted for diagnostic potential and SFN, SLIT2 and SERPINB5 for prognostic potential.
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1. Introduction
Prostate cancer (PCa) is one of the most common
malignancies affectingmen and is a major public health
problem likely to increase in magnitude with an in-
creasingly aged population. Prostate specific antigen
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(PSA) screening for PCa is widely used in the USA,
which also has the highest reported incidence world-
wide [1]. Despite poor specificity, PSA is valuable for
early detection of PCa. The anticipated wider adop-
tion of PSA screening in Europe will lead to increases
in reported incidence of PCa, possibly reaching levels
seen in the USA. While PSA screening decreases the
absolute risk of death fromPCa, the lives saved come at
a price of invasive examinations and biopsy of healthy
men, risk of over-diagnosis and over-treatment as well
as increased health care burden [2,3]. It is estimated
that to save one life, 1410 men need to be screened
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resulting in 48 additional cases of unnecessarily diag-
nosed cancer [2]. One of the main reasons for this
unsatisfactory situation is the biology of PCa, a large
proportion of which is essentially harmless and will not
result in significant morbidity or death if left untreated.
Unfortunately, current PCa screening methods cannot
identify the harmful cancers and thus the desired goal
of an ideal screening remains unrealized. Therefore,
a need for better screening, diagnosis, prognosis and
treatment strategies and overall better biomarkers of
prostate disease assessment is clearly evident.
Gene silencing and reactivation, effected in-part by
DNA methylation or demethylation of CG dyads in
CpG islands, is a key control mechanism in cellular
differentiation, development, and disease [4–6]. Aber-
rant DNA methylation and the associated deregulation
of gene expression are believed to play pivotal roles in
cancer development and progression [7]. As these ab-
normalities can be measured, their careful mapping in
candidate genes may identify novel biomarkers. One
of the earliest [8] and often [9–17] reported abnormal-
ities arising during prostate carcinogenesis is hyper-
methylation of the GSTP1 gene detected in > 90%
of cancers but not in normal tissues [18]. In contrast
to GSTP1, the majority of data for other investigated
genes come from isolated reports and small studies,
e.g. HIN1 [19] and BCL2 [17]. Also, there are evi-
dent inconsistencies between the reports for genes such
as DAPK1 [12,13], CDKN2A [12,14,17], CDH1 [11,
20] and EDNRB [12,20], consequently their methyla-
tion status and biomarker potential remains uncertain.
A majority of previous studies employed methylation-
specific polymerase chain reaction (MSP) [21] or quan-
titative real-time MSP [22] to assess methylation sta-
tus and often artificially categorized the data into sim-
plistic hypermethylated or hypomethylated categories.
Despite common use, these methods have known dis-
advantages such as false-positive and false-negative re-
sults, as well as use of relative comparisons instead of
absolute quantification.
Numerous studies report aberrant promoter and ex-
on/intron methylation in a growing list of genes in-
volved in tumor suppression, hormonal response, sig-
naling, cell cycle control and tumor cell invasion. If
carefully characterized in an appropriate set of steps in-
volving credentialing, verification and validation as de-
scribed by the Early Detection Research Network [23],
some of these genes can fulfill the strong need for
specialized individual biomarker assays. Our study
was designed to select interesting markers for valida-
tion in large prospective cohorts with known survival
outcomes such as the Trans Atlantic Prostate Group
(TAPG) cohort [24]. We selected candidate genes from
the published literature to cover a wide range of cellu-
lar pathways since these genes are more likely to pass
successfully through the validation pathway. Indeed
such an approach has been very productive in the past,
resulting in a widely used clinical assay Oncotype Dx
for breast cancer. Therefore, we focused on three main
groups. The first group consisted of genes that have
repeatedly been shown as aberrantly methylated in var-
ious prostate malignancies – GSTP1 [8–17], RARB [9,
13,16,17,25], APC [10,12,16,17,26], RASSF1A [9–12,
16,17,20], CDH1 [11,12,20], CDKN2A [11,12,14,17],
TIG1 [16,17,25], MDR1 [10,12,17], EDNRB [12,20],
and PTGS2 [10,12,15]. The second group consist-
ed of genes that have been occasionally reported as
differentially methylated in PCa – CCND2 [16,26],
ESR1 [9,12], DAPK1 [12,13], SFN [27], DPYS [28],
NKX2-5 [9,28], PDLIM4 [15], BCL2 [17], HIN1 [19],
MCAM [29], EGFR5 [28], and CDH13 [11]. The third
group comprised genes that have displayed interesting
potential in cancers other than prostate – MAL [30],
THRB [31], SLIT2 [32], HLAa [33], TWIST1 [34], and
SERPINB5 [35].
To quantify DNA methylation in the most accurate
available way, we chose to use PCR followed by py-
rosequencing (PSQ). This is a sensitive and highly re-
produciblemethod [36] that is uniquely suited for DNA
methylation analyses of clinical specimens yielding
small amounts of DNA. Unlike most other methods, it
provides absolute quantitative information on bases at
each interrogated CG site. The assay design readily
allows the interrogation of different parts of the gene(s)
of interest as well as inclusion of internal controls to
address inaccuracies resulting from incomplete bisul-
fite conversion. In addition, the PSQ method can be
used to analyze up to a hundred genes in a large number
of specimens using automated workstations and obtain
data from limited amounts of DNA which would not
be possible with high-throughput microarrays.
We investigated methylation of the 28 genes in a
well-annotated clinical specimen set comprising be-
nign prostatic hyperplasia (BPH) and PCa (Table 1).
The main aims were to identify genes where devia-
tion in methylation patterns can reliably differentiate
between benign and malignant prostate tissues as well
as to explore associations between gene methylation
and Gleason score as a surrogate indicator of disease
outcome. In addition, as there have been only a few
published reports using the PSQ method, our gene se-
lection approach also offered an opportunity to test the
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Table 1
Clinical and pathological characteristics of the 29 BPH
and 48 PCa studied
BPH PCa
Age (years) Range 60–87 39–78
Average 76 65∗
Gleason score 6 9
7 23
8 7
9–10 9
PSA (ng/ml) < 4 3 0
4–9.9 3 12
10–20 1 10
> 20 0 13
Unknown 22 13
Source of tissue TURP 29 6
Prostatectomy 37
Unknown 5
∗3 missing values.
reproducibility of the method on the more important
of the current candidate genes as well as to compare
to the data obtained with methods producing relative
measurements.
2. Materials and methods
2.1. Human prostate tissue specimens
The study set included fresh frozen prostate tissue
from 77 patients of which 48 were diagnosed with can-
cer and 29 as BPH. Specimens were collected either af-
ter radical prostatectomy, transurethral resection of the
prostate (TURP) or TURP in cancer patients (channel
TURP) (Table 1). Specimens were collected from three
different sites, Changhai Hospital in Shanghai, China,
Whipps Cross Hospital, London and St Bartholomew’s
Hospital, London during the period 1996–2008. All
specimens were centrally reviewed to confirm diag-
nosis by expert genitourinary pathologists (DB, YY).
Gleason grading was performed by modern standard-
ized criteria [37].
Informed consent was obtained from all patients.
UK national approval was obtained from the Northern
Multi-Research Ethics Committee, followed by local
ethics committee approval from each of the collabo-
rating hospital trusts. Ethical approval from Chang-
hai Hospital Ethics Committee was obtained for the
Chinese specimens.
2.2. DNA extraction and bisulfite conversion
Genomic DNA was extracted from 2–3 10 μm slices
of the fresh frozen material using QIAamp DNA Mini
Kit (Qiagen Inc., Hilden, Germany) and quantified by
UV absorption, typically yielding in total > 1 μg of
DNA per specimen. 120–300 ng of DNA was used
in the bisulfite conversion reactions where unmethy-
lated cytosines were converted to uracil with the Epi-
Tect Bisulfite kit (Qiagen) according to manufactur-
er’s instructions. Briefly, DNA was mixed with water,
DNA protect buffer and bisulfite mix and the conver-
sion was run in a thermocycler (Biometra, Goettingen,
Germany) at the recommended cycle conditions. Con-
verted DNA was purified on a spin column and eluted
twice into a total of 40 μl Buffer EB.
2.3. PCR and pyrosequencing
Primer sets with one biotin-labelled primer were
used to amplify the bisulfite converted DNA. New
primers for each of the 28 genes (gene names follow the
UCSC gene nomenclature system http://genome.ucsc.
edu/) were designed using PyroMark Assay Design
software version 2.0.1.15 (Qiagen); where possible
primers were designed to keep amplicons short with
lengths between 90 to 140 base pairs (bp) to facilitate
later studies of formalin-fixed paraffin-embedded (FF-
PE) specimens. The size of the amplicons was restrict-
ed to amaximumof 210 bp. All primerswere located in
promoter or first exon CpG islands identified by Meth-
Primer [38], depending on where the design of the as-
say allowed for optimal primers (Supplementary mate-
rial Table S1). Due care was taken to avoid any primer
overlapping CG dyads to prevent amplification biases.
Median size of all amplicons was 104 bp. For genes,
previously investigated by othermethods, primerswere
positioned to investigate the same CGs or ones in close
vicinity. For some genes e.g. CDH1, GSTP1, we ex-
amined two different sites within the CpG island sep-
arated by several hundred base pairs. To provide the
internal control for total bisulfite conversion, a non-CG
cytosine in the region for pyrosequencingwas included
where possible.
PCRs were performedusing a convertedDNA equiv-
alent of 200 cells employing the PyroMark PCR kit
(Qiagen). The cell genome-equivalents of DNA cal-
culations assumed 6 pg DNA per diploid cell. Briefly,
12.5 μl master mix, 2.5 μl Coral red, 5pmol of each
primer, 7 μl of water and 2 μl sample were mixed for
each reaction and run at thermal cycling conditions:
95◦C for 15 min and then 45 cycles: 30 sec at 94◦C; 30
sec at the optimized primer-specific annealing temper-
ature (Supplementarymaterial Table 1); 30 sec at 72◦C
and a final extension for 10 min at 72◦C. The amplified
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DNA was confirmed by electrophoresis in a 2% low
melting point agarose gel (Sigma-Aldrich, Steinheim,
Germany) in TBE buffer or by the QiaExel capillary
electrophoresis instrument (Qiagen).
A standard pyrosequencing sample preparation pro-
tocol was applied [39]. 3 μl streptavidin beads (GE
Healthcare, Buckinghamshire, UK), 37 μl PyroMark
binding buffer (Qiagen), 20 μl PCR product and 20 μl
water were mixed and incubated for 10 min on a shak-
ing table at 1300 rpm. Using the Biotage Q96 Vac-
cum Workstation, amplicons were separated, dena-
tured, washed and added to 45 μl annealing buffer con-
taining 0.33 μM of pyrosequencing primer. Primer an-
nealing was performed by incubating the samples at
80◦C for 2 min and allowed to cool to room tempera-
ture prior to pyrosequencing. PyroGold reagents were
used for the pyrosequencing reaction and the signal
was analyzed using the PSQ 96MA system (Biotage,
Uppsala, Sweden). Target CGs were evaluated by in-
strument software (PSQ96MA 2.1) which converts the
pyrograms to numerical values for peak heights and
calculates proportion of methylation at each base as a
C/T ratio. All runs contained standard curves, which
comprised a range of control methylated DNA (0%,
25%, 50%, 75%, and 100%) to allow standardized di-
rect comparisons between different primer sets. For
the standard curves a total of 300 ng of unmethylated
(Qiagen) and hypermethylated DNA (Millipore, Bil-
lerica, MA, USA) were mixed to obtain the different
ratios of DNA methylation and then bisulfite converted
as described above.
2.4. Statistical analyses
The main analyses were based on mean values of
all CG analyzed. The number of CGs analyzed varied
between two to six in each gene as allowed by software-
defined parameters. To limit numbers of assays run,and
costs, genes that showed no potential in differentiating
between BPH and cancer or between low and high
Gleason score were investigated in fewer specimens.
Methylation differences between the tissues were ex-
amined by Mann-Whitney test. To account for the high
number of genes tested on the same data, the Benjamin
and Hochberg step-up procedure for controlling false
discovery rate (FDR) was appliedwith FDR of 1% [40].
To explore the relationship between gene methyla-
tion and age, methylation was normalized by z-scores,
where the raw methylation minus the sample mean was
divided by the sample standard deviation. Association
between methylation and age was explored by Spear-
man’s test, while for methylation versus Gleason score,
the Cuzick trend test was used [41]. For cases with
a PSA measurement, the association with methylation
was using Spearman’s rank test. Further, Spearman co-
efficients, based on rank orderings of raw gene methy-
lation in all cancers, were calculated to explore cor-
relation in methylation between genes. The cut-offs
chosen to present true-positive rates (TP, proportion
of cancers correctly classified) and false-positive rates
(FP, proportion of non-cancers incorrectly flagged) by
gene were chosen using the same cost function for all
genes – namely, to minimize FP – TP.
To help investigate methylation associated with high
Gleason scores, a random forest classification algo-
rithm [42] was applied. Plots were used to inspect the
genes identified by the random forest, with classifica-
tion boundaries added from linear discriminant analy-
ses. Gleason score classification accuracy 95% con-
fidence intervals (CI) were based on a non-parametric
bootstrap method with 1,000 resamples. All statisti-
cal calculations were conducted using software R ver-
sion 2.9.2 [43]. Rejection of the null hypothesis was
assumed at an α < 0.05.
3. Results
3.1. Descriptive statistics of candidate gene
methylation
The reproducibility of the PSQ method was investi-
gated at the outset by measuring methylation of GSTP1
on three separate occasions. The mean methylation
difference between highest and lowest reading for the
same sample was 7% for BPH cases, and 13% for can-
cers; the Pearson correlation for runs 1 vs. 2 was 0.90
whereas between runs 1 and 3 was 0.97. This concor-
dance was regarded as acceptable and all subsequent
data were based on single measurements.
Methylation data were adjusted for primer bias
through re-scaling each gene’s methylation measure-
ments by the median standard curve obtained for each
primer set. The impact of applying these corrections
to the genes had small effects on median methylation
differences (Supplementary material Fig. S1) but al-
lowed comparison across different genes. Of the 28
genes studied, methylation of 20 genes: RARB, HIN1,
BCL2, GSTP1, CCND2, EGFR5, APC, RASSF1A,
MDR1, NKX2-5, CDH13, DPYS, PTGS2, EDNRB,
MAL, PDLIM4, SERPINB5, HLAa, ESR1 and TIG1
could distinguish prostate cancer from BPH tissue at
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Table 2
The proportion of cancers correctly classified (true positive,
TP) and the proportion of BPH incorrectly classified (false
positive, FP) when the best cut off from the primer adjusted
data was used. Genes with FP above 50% are excluded
Gene Cut off (% methylation) TP (%) FP (%)
RARB 20.8 100 0
GSTP1 7.3 98 0
HIN1 26.5 98 0
APC 26.5 96 0
BCL2 10.4 96 3
CCND2 7.5 92 0
CHD13 27.5 88 0
EGFR5 35.5 96 14
NKX2-5 32.5 88 0
RASSF1A 14.8 92 7
DPYS 37.9 85 0
MDR1 26.8 85 3
PTGS2 13.8 79 0
EDNRB 33.5 77 0
MAL 3.8 85 14
PDLIM4 8 75 3
HLAa 6.11 74 14
TIG1 4.8 65 10
ESR1 38.5 62 7
SLIT2 33.5 56 14
CDKN2A 35.5 40 0
MCAM 1.4 45 18
SFN 96.5 15 3
THRB 27.5 26 21
CDH1 13.2 33 14
TWIST1 3.8 56 38
FDR of 1% (Fig. 1, Supplementary material Table S2).
Cut-off levels were calculated to evaluate the diagnos-
tic potential of methylation differences (Table 2). This
allowed dichotomization of the data, where a cut-off of
21% methylation of RARB separated all cancers from
BPH with 100% accuracy, i.e. TP = 100%, FP = 0%.
In BPH specimens, EGFR5, DPYS, ESR1, MDR1,
SERPINB5 and SFN displayed median methylation
above 10% whereas most other genes were unmethy-
lated (median methylation ∼ 2%) (Fig. 1). In particu-
lar, SERPINB5 and SFN were methylated to approxi-
mately 50% in BPH. Furthermore, SERPINB5 was the
only gene with significantly higher methylation in BPH
than cancers (p < 0.001) (Fig. 1). MCAM, CDKN2A,
THRB, TWIST1, CDH1 and DAPK1 were methylated
below 10% in both BPH and PCa (Fig. 1, Supplemen-
tary material Table S2).
3.2. Association between clinical covariates and gene
methylation
The relationship among genemethylation levels,age,
Gleason score and PSA levels were explored in the
PCa. There was a positive association of Gleason score
with age (p < 0.001) and PSA (p = 0.0013), though
no association between PSA and age (p = 0.22) (data
not shown).
Therewas a positive trend between age and standard-
ized mean methylation values across all genes, akin
to global methylation status, for each case (Pearson
correlation 0.52, p < 0.0001; Fig. 2a). Furthermore,
inspection of the distribution of p-values suggested a
moderate effect of age common to the methylation of
all genes, while Gleason score appeared to affect only
subsets of genes (Fig. 2b). The methylation levels of
NKX2-5 and APC (p = 0.009), TIG1, ESR1, GSTP1
(p = 0.01), CDH13, EGFR5 (p = 0.02), MCAM (p =
0.03) and SLIT2 (p = 0.04) showed a positive asso-
ciation with age (Supplementary material Table S3).
The Cuzick trend test showed that the methylation of
SFN (p = 0.01), TIG1 (p = 0.02), PDLIM4, APC
and SERPINB5 (p = 0.04) were associated with Glea-
son score (Supplementary material Table S3). More-
over, according to random forest classification, high
methylation of SFN, SLIT2 and SERPINB5 separated
low from high Gleason score cancers. The linear dis-
crimination boundaries described the structure found
by the random forest classification (Fig. 3). Methyla-
tion level composite measure of SFN and SERPINB5
correctly classified 81% (95% CI 56–91) of high Glea-
son scores while 23% (9–47) of low Gleason scores
were misclassified. Similarly, methylation of SFN and
SLIT2, detected 62% (47–81) of high and misclassified
12% (9–47) low Gleason scores while methylation of
SERPINB5 and SLIT2 detected 62% (47–81) of high
and misclassified 13% (3–31) of low Gleason scores
(Fig. 3).
Methylation levels of 17 genes: HIN1, TWIST1,
GSTP1, RARB (p < 0.001), HLAa, BCL2, APC,
PDLIM4, PTGS2, DPYS, CDH13 (p < 0.01) and
RASSF1A, MDR1, EGFR5, EDNRB, TIG1, CCND2
(p < 0.05) were positively associated with PSA (Sup-
plementary material Table S3). Furthermore, methy-
lation levels of most genes that could distinguish be-
tween BPH and cancer e.g. RARB,APC, EGFR5,HIN1,
RASSF1A, PTGS2 and CDH13 were moderately corre-
lated (Fig. 4).
4. Discussion
Other than PSA, with all its limitations, no generally
accepted validated biomarkers are currently available
for prognosis or therapeutic prediction in prostate can-
cer. Although several new markers such as PCA3 [44],
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Fig. 1. The distribution of methylation measurements for a set of candidate genes in prostate cancer (PCa) and benign prostatic hyperplasia
(BPH). The genes were rank ordered by Mann-Whitney statistics (Supplementary material, Table S2) throughout a-d. The primer unadjusted
level of methylation of each gene is demonstrated as pairs of results with BPH corresponding to the boxplot on the left and PCa as the boxplot
on the right. The differences in methylation of the tissues divided the genes in a, b and c) into those most likely to distinguish and d) not likely to
distinguish BPH from PCa at FDR below 1%. Whiskers of the boxplot mark the 5th and 95th percentiles, the box 25th percentile, median and
75 percentile, while extreme values are shown by (•).
Fig. 2. a) Average methylation by age. Each point in the plot represents a case and corresponds to the average methylation across all the genes
tested for that case. The level of methylation is on the y-axis and age on the x-axis. There appears to be a trend of increasing methylation with age
as shown by the fitted line (y = −1.6832 + 0.02631 x, where y and x refer to values of methylation level and age on respective axes). b) The
empirical cumulative distribution of p values from tests of an association between methylation and age (solid line), and methylation and Gleason
score (dashed line) Supplementary material, Table S3. The x-axis shows the p value and the y axis gives the empirical cumulative distribution
[Fn (x)]. Under the null hypothesis of no association, a diagonal straight line is to be expected.
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Fig. 3. Methylation values of high Gleason (> 7, triangle) and low Gleason score (circle) cases for three pairs of genes. The separating lines
show linear discrimination boundaries that were fitted to classify high from low Gleason score. The aim was to separate these two categories as
much as possible. The genes plotted are A) SFN and SERPINB5, B) SFN and SLIT2, C) SERPINB5 and SLIT2.
Fig. 4. Heatmap of Spearman correlation of methylation between each pair of genes. The shade depends on the absolute correlation; negative
correlations are marked with (−) in the cell. Higher correlation indicates a more similar ranking of all cases by methylation than lower correlation.
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TMPRSS-ERG [45], Ki-67 [46], HSP27 [47] and oth-
ers are under consideration, they are not validated for
widespread use and thus Gleason score and PSA in the
context of other clinical information remain the main-
stay of decision making in PCa [24].
Alterations in DNA methylation contribute to devel-
opment and progression of PCa [7], and studying the
methylation of genes involved in carcinogenesis is like-
ly to reveal useful novel biomarkers that could eventu-
ally be validated for PCa. This is the first study to quan-
tify methylationof a large number of candidate genes in
a common set of prostate clinical specimens by means
of a single highly accurate and validatedDNA methyla-
tion assay. It demonstrates the methylation patterns of
28 genes with a clear aim to identify candidatemethyla-
tion biomarkers with diagnostic and/or prognostic po-
tential to be validated in large cohort studies. Such val-
idation in the TAPG series comprising over 1000 FFPE
PCa tissues is underway. Our robust PSQ approach
is particularly suited to situations where the available
specimen set for molecular studies is highly limited in
either quality or amount. Assays were specifically de-
signed for use in FFPE material limiting the amplicon
size but covering a reasonable number of CG. In addi-
tion, our preliminary data show that methylation levels
in frozen and matched FFPE specimens are equivalent
(Supplementary material Table S4). To fine-tune the
PSQ method, predefined quantitative controls were in-
cluded within each experiment to allow the adjustment
of all data and thus improve the accuracy of compar-
isons in levels of methylation between the investigat-
ed genes. Internal controls to check completeness of
bisulfite conversion were also included in the assays.
This is an important advantage of the PSQ method in-
creasing the measurement accuracy compared to other
commonly used methods. The absolute measurements
obtained by PSQ were in good agreement to previous
reports using relative measurements [48].
Twenty of the investigated genes, namely RARB,
HIN1, BCL2, GSTP1, CCND2, EGFR5, APC,
RASSF1A, MDR1, NKX2-5, CDH13, DPYS, PTGS2,
EDNRB, MAL, PDLIM4, SERPINB5, HLAa, ESR1 and
TIG1 were more highly methylated in cancers than
BPH tissue (Fig. 1) while the risk of false discovery
(FDR) was less than 1%. To the best of our knowledge,
the methylation of MAL, HLAa, SERPINB5, THRB,
TWIST1 and SLIT2 was demonstrated here for the first
time in prostate tissue. While THRB and TWIST1 were
overall unmethylated, HLAa and MAL displayed low
methylation with fair ability to discriminate between
the tissues with median difference 15% and 7% respec-
tively (Fig. 1a). Methylation status of HLAa was as-
sociated to level of PSA (Supplemental material Ta-
ble S3) but not age, Gleason score or methylation of
other genes (Fig. 4). This merits further study as a diag-
nostic biomarker. The methylation of SLIT2 was low,
however, median methylation was elevated in cancers
∼6% vs.∼ 2% in BPH and moreovermethylation level
of SLIT2 could separate high and low Gleason score
cancers indicating possible prognostic characteristics
(Fig. 3).
Average methylation of SERPINB5 and SFN was
lower in cancers than in BPH, differences of 15% (p <
0.001) and 12% (p = 0.05) respectively (Supplemen-
tary material Table S2). Interestingly, for both genes
in PCa the quantitatively higher levels of methylation
were associated with high Gleason score (Fig. 3). SFN
is regarded as a tumor suppressor gene and the encoded
14-3-3σ protein interacts with cyclins to arrest the cell
cycle when induced by the p53 pathway in response
to DNA damage [49]. SERPINB5 is another putative
tumor suppressor gene, expressing the maspin protein
which is involved in signal transduction and response to
cellular stress [50]. Permanent silencing of these genes
may render the cell defenseless towards accumulation
of additional DNA damage during cellular stress and
therefore play a role in progression of the malignancy
to high nuclear grade. However, our data are not con-
sistent with a simplistic tumor suppressor gene silenc-
ing mechanism as the basis for cancer progression. On
the contrary the higher level of methylation in normal
tissue and variable changes in level depending on Glea-
son score suggest complex regulation of methylation
of these genes during progression. Higher methyla-
tion level of SFN in cancers than high-grade prostatic
intraepithelial neoplasia (HGPIN) [27] as well as up-
regulation of maspin expression in HGPIN and loss of
its expression with progression has been previously ob-
served [51] and underscores the prognostic potential of
these genes. In addition, the methylation of SFN and
SERPINB5 were approximately ∼50% in BPH, per-
haps suggesting methylation of only one allele. Since
the relatively small changes in DNA methylation lev-
els of SFN and SERPINB5 seemingly have significant
effects on disease risk assessment, measurement by a
very accurate method such as PSQ may be a necessity.
MCAM was unmethylated in the investigated spec-
imens (Fig. 1d) despite that the aberrant methylation
of the MCAM promoter in PCa was previously report-
ed [29]. Investigation of different CG sites within the
promoter by different methods could be the reason for
this discrepancy.
N. Vasiljevic´ et al. / Absolute quantitation of DNA methylation of 28 candidate genes 159
Reports of methylation of DAPK1, CDH1 and CD-
KN2Ahave been inconsistent. Weobserved equally low
(median< 10%)methylation of these genes inBPHand
cancer tissues, although non-significant differences of
small magnitude were observed (Supplementary mate-
rial Table S2, Fig. 1d). For CDH1, this observation was
true for both promoter regions previously reported to
show differences in methylation [52]. These inconsis-
tencies may be due to amplification of non-significant
differences by a semi-quantitative method resulting in
skewed proportions of methylation. In addition, these
genes appeared to have little association with Gleason
score or PSA levels (Supplementary material Table S3)
and since prognostic value has so far not been evident,
we believe that these genes have poor value as biomark-
ers in PCa.
Baseline PSA data were available for only 35 can-
cers, nonetheless methylation of HIN1 was positively
associated with PSA (p < 0.001) with no evidence of a
concurrent association with age or Gleason score (Sup-
plementary data Table S3). Although, HIN1 methy-
lation has not yet been linked to disease prognosis,
the protein’s suggested role in preventing invasion [53]
strengthens its possible role in cancer progression. Ex-
cept for TWIST1, 16 of the genes showing difference
between cancer and BPH were also positively associat-
ed with PSA (p < 0.05) (Supplementary data Table S3)
further supporting their diagnostic potential.
Similar to numerous previous reports, we observed
that gene methylation increased with age which was
identified as the strongest covariate (Fig. 2). Therefore
the need for appropriate adjustment for age or inclusion
of age in statistical models in future DNA methylation
studies cannot be overemphasized. A recent study us-
ing the PSQ method showed the correlation of age and
methylation of RARB, RASSF1a and GSTP1 in normal
tissue [9].
This study should be regarded as a preliminary ex-
ploration and has a number of limitations including that
the specimen set was not blinded and there were no
comparisons to other well respected DNA methylation
methods such as bisulfite sequencing. However, inclu-
sion of quantitative controls in every experimental run
and inclusion of non-CpGC controlswherever possible
as well as the strong agreement in methylation levels
of GSTP1 detected in our study and by other investi-
gators, using a variety of different methods, ensured
reliability of our assays. Additional validation of our
findings is important in order to establish the clinical
utility of these biomarker sets.
In summary, PSQ is a useful and accurate method
for studying methylation of genes. A great number
of genes are methylated in PCa and the methylation
of many genes is correlated with each other (Fig. 4),
in particular RARB, APC, EGFR5, HIN1, RASSF1A,
PTGS2 and CDH13, possibly indicating a concerted
mechanism. While age displays a common effect on
gene methylation, methylation of SFN and SERPINB5
may be specific to progression of PCa and deserves
further study. Overall, 20 of the 28 investigated genes
were able to distinguish between BPH and cancer tis-
sues, some with good and others, e.g. RARB, with per-
fect discrimination abilities. Our results further suggest
that while methylation status of some genes demon-
strates most promising characteristics for diagnosis,
such as RARB, HIN1, HLAa and GSTP1 others such as
SFN, SLIT2 and SERPINB5 deserve further validation
as prognostic markers.
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